Solvay "sell"

01/09/06 - Merrill Lynch

LONDON, January 9 (newratings.com) - Analysts at Merrill Lynch maintain their "sell" rating on Solvay (SOL). The fair value is set to €82.

In a research note published this morning, the analysts mention that the company is witnessing increased competitive pressure at its Tricor franchise. The recent key trial data from Solvay's Tricor for the long-term treatment of diabetes did not show statistically significant results, the analysts say. The company's performance during 2H06 is likely to be adversely affected by an anticipated slowdown in the PVC market, Merrill Lynch adds.